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Abstract: Due to the limitations of current treatment regimes, gene therapy is a promising strategy
being explored to correct blood glucose concentrations in diabetic patients. In the current study,
we used a retroviral vector to deliver either the human insulin gene alone, the rat NeuroD1 gene
alone, or the human insulin gene and rat NeuroD1 genes together, to the rat liver cell line, H4IIE,
to determine if storage of insulin and pancreatic transdifferentiation occurred. Stable clones were
selected and expanded into cell lines: H4IIEins (insulin gene alone), H4IIE/ND (NeuroD1 gene
alone), and H4IIEins/ND (insulin and NeuroD1 genes). The H4IIEins cells did not store insulin;
however, H4IIE/ND and H4IIEins/ND cells stored 65.5 ˘ 5.6 and 1475.4 ˘ 171.8 pmol/insulin/
5 ˆ 106 cells, respectively. Additionally, several β cell transcription factors and pancreatic hormones
were expressed in both H4IIE/ND and H4IIEins/ND cells. Electron microscopy revealed insulin
storage vesicles in the H4IIE/ND and H4IIEins/ND cell lines. Regulated secretion of insulin
to glucose (0–20 mmol/L) was seen in the H4IIEins/ND cell line. The H4IIEins/ND cells were
transplanted into diabetic immunoincompetent mice, resulting in normalization of blood glucose.
This data shows that the expression of NeuroD1 and insulin in liver cells may be a useful strategy for
inducing islet neogenesis and reversing diabetes.
Keywords: diabetes; gene therapy; H4IIE cells; regulated insulin secretion; insulin storage; secretory
granules; liver cells; β cell transcription factors; furin-cleavable human insulin
1. Introduction
Diabetes mellitus is a chronic metabolic disorder of multiple etiologies [1,2]. The condition
is characterized by chronic hyperglycaemia caused by immune-mediated beta (β) cell elimination
or defects in insulin secretion and/or insulin action [1]. According to the International Diabetes
Federation (IDF) [3], 415 million people have diabetes, and estimate that one person will die from
diabetes-related conditions every six seconds. By 2040, it is estimated that 642 million people will
have diabetes.
Diabetes is classified into three categories: type 1 diabetes mellitus (T1D), type 2 diabetes mellitus
(T2D), and gestational diabetes [1]. T1D is caused by an absolute insulin deficiency, secondary to
the autoimmune destruction of the insulin-secreting pancreatic β-cells [1]. T2D is characterized by
insulin deficiency or insulin secretory defects, either with or without insulin resistance, and may be
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treated with oral medications, lifestyle, and dietary modifications; however, a large proportion of
patients become insulin-dependent due to β-cell dysfunction. Gestational diabetes is characterized
by hyperglycaemia caused by the inability to compensate for increased insulin demands during
pregnancy [1].
Tight glucose control, through intensive insulin therapy, in insulin-dependent individuals, delays,
but does not eliminate, complications such as nephropathy, retinopathy, cardiovascular disorders, and
various neurological problems, which greatly increase mortality and morbidity [4]. β-Cell replacement
is a promising approach for the treatment of diabetes; however, transplantation of pancreatic tissue
is limited by a shortage of donors and the need for lifelong immunosuppression, which carries
detrimental side effects. Thus, alternative therapeutic strategies must be developed. Gene therapy
is one such strategy. The production of an insulin-secreting β-cell line, which is either resistant to
recurrent autoimmunity, or able to modulate the immune system to induce tolerance, is required to
reverse insulin-dependent diabetes. The importance of transcription factors in the regulation of cell
fate during embryonic development has been widely demonstrated. The budding of the pancreas
from the endoderm layer requires expression of the pancreatic transcription factor, Pdx-1. Subsequent
pancreatic organogenesis is critically dependent upon the spatial and temporal expression of Pdx-1, and
other pancreatic transcription factors [5]. NeuroD1 is expressed immediately downstream of Neurog3
in all pancreatic endocrine progenitors and is maintained in all later stages of β-cell development.
It is also an activator of the insulin gene [6]. The knockout studies of NeuroD1 in mice [7] resulted in
reduction in the number of pancreatic β-cells and indicate the importance of NeuroD1 in regulating the
proliferation of endocrine cell lineages.
Due to the common endodermic origin of the liver and pancreas in the embryo [5], the ability
to transdifferentiate tissue from liver to pancreas has been examined to a greater extent than other
tissue types [8]. One approach is the delivery of β-cell transcription factors to the liver to generate the
production of insulin-producing cells [9–13]. Our laboratory, and others, have shown that the ability
of liver cells to both store and secrete insulin and undergo pancreatic differentiation is linked to the
expression of β-cell transcription factors [8–18]. We had previously observed that expression of the
insulin transgene in a human liver cell line, Huh7, which endogenously expresses β-cell transcription
factors, resulted in pancreatic transdifferentiation with the formation of insulin storage granules
and regulated secretion of insulin to glucose. After transplantation into diabetic non obese/severe
combined immunodeficiency (NOD/scid) mice, hyperglycaemia was reversed [11]. We have also
observed that the delivery of furin-cleavable human insulin (INS-FUR) directly to the livers of
chemically-diabetic rats, spontaneously-diabetic NOD mice, and pancreatectomized pigs, resulted in
the spontaneous expression of β-cell transcription factors, secretory granule biogenesis, reversal of
diabetes, and normal glucose tolerance [16–18].
In the current study, we used a bicistronic retroviral vector to deliver either the INS-FUR gene
alone, or the INS-FUR gene [19] and the rat NeuroD1 gene together, to the rat liver cell line, H4IIE
which, like normal primary hepatocytes, does not express the key β-cell transcription factors, to
determine if the storage of insulin and pancreatic transdifferentiation could be induced. There are
many choices of delivery of transgenes into cells [20]; however, viral vectors remain the most efficient
way. A retroviral vector was used in this model system as it allows efficient integration of transgenes
into the host genome, with long term expression and selection of stable clones possible via selection
in G418 [21]. INS-FUR was used, rather than transduction with the rat insulin gene, in order to
distinguish transgene and endogenous rat insulin gene expression levels. Additionally, normal liver
cells do not have the insulin proconvertase enzymes that cleave proinsulin to insulin and c-peptide;
hence, in this system mature insulin is produced from the INS-FUR construct following cleavage with
furin, which is expressed in liver cells.
Briefly, the results of the study showed that the expression of INS-FUR together with the β-cell
transcription factor NeuroD1 in the H4IIEins/ND cell line had a synergistic effect leading to pancreatic
transdifferentiation, storage of insulin in granules, regulated insulin secretion to glucose (and other
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β-cell secretogogues), and expression of a number of β-cell transcription factors and pancreatic
hormones and ultimate reversal of diabetes. By comparison, expression of INS-FUR alone resulted in
constitutive expression of insulin (H4IIEins), and NeuroD1 alone (H4IIE/ND) resulted in expression of
β-cell transcription factors together with some pancreatic hormones; however, insulin storage was low
and no glucose-regulated insulin secretion was detected.
2. Results
2.1. Insulin Secretion and Storage
In order to determine if the transduced cell lines stored and secreted human and/or rat insulin,
culture supernatants and acid-ethanol extracts were examined using specific commercial ELISA kits.
It can be seen from Table 1 that, as expected, H4IIE cells transduced with the empty vector
(H4IIE-EV) did not store or secrete either human or rat insulin. H4IIEins cells secreted human
insulin, but did not store any insulin. H4IIEins cells did not secrete or store rat insulin. By
comparison H4IIE/ND and H4IIEins/ND cells stored and secreted both human and rat insulin
following transduction, however H4IIEins/ND cells stored and secreted significantly higher amounts
of both human and rat insulin compared to other cell lines. In comparison, the mouse β-cell
line, MIN6 [22] which was used as a positive control in the electron microscope studies, stored
1678.0 ˘ 215.7 pmol/mouse insulin/5 ˆ 106 cells.
Table 1. Insulin secretion and storage from transduced H4IIE cell lines.
Cell Line
Human Insulin Rat Insulin
Secretion Storage Secretion Storage
H4IIE ND ND ND ND
H4IIE-EV ND ND ND ND
H4IIEins 0.5 ˘ 0.01 ND ND ND
H4IIE/ND 4.2 ˘ 0.9 65.3 ˘ 5.6 1.0 ˘0.1 2.2 ˘ 0.4
H4IIEins/ND 32.1 ˘ 2.1 * 1475.4 ˘ 171.2 * 3.1 ˘ 0.9 * 6.3 ˘ 1.4 *
* Insulin secretion is expressed as pmol insulin/5 ˆ 106 cells/24 h and insulin storage as pmol/insulin/
5 ˆ 106 cells. Cell lines were H4IIE (parent cell line), H4IIE-EV (empty vector), H4IIEins (INS-FUR gene alone),
H4IIE/ND (rat NeuroD1 gene alone), H4IIEins/ND (INS-FUR and rat NeuroD1 genes); ND: not detectable.
Asterisks represent a significantly higher value compared to other cell lines. Values are expressed as means ˘ SE
(n = 3).
The effect of three common β-cell stimuli (glucose, calcium, and theophylline) on the insulin
secretion of the H4IIEins, H4IIE/ND, and H4IIEins/ND cells was determined. H4IIEins cells did not
secrete increased amounts of insulin in response to stimulation with glucose, calcium, or theophylline.
In response to varying concentrations of glucose (0–20 mmol/L), a dose-response curve for human
insulin secretion was generated for H4IIEins/ND cells (Figure 1A). Whilst glucose-responsiveness
started at a slightly lower concentration than seen in normal pancreatic islet cells, the secretion curve
generated by H4IIEins/ND cells approached normal physiological levels. H4IIE/ND cells were not
responsive to a glucose stimulus (Figure 1A). It was not possible to detect rat insulin secretion by static
incubation, most likely because the levels were too low to detect using the assay system available.
A >20-fold and a six-fold stimulation of human insulin secretion above basal levels was detected
when 10 mmol/L theophylline was applied as a stimulus to H4IIEins/ND cells and H4IIE/ND cells,
respectively (Figure 1B). H4IIEins/ND cells showed a 4.5-fold increase in basal insulin secretion to a
stimulus of 10 mmol/L calcium; however, H4IIE/ND cells were not responsive to the calcium stimulus
(Figure 1C).
Int. J. Mol. Sci. 2016, 17, 534 4 of 14
Int. J. Mol. Sci. 2016, 17, 534 4 of 14 
 
 
Figure 1. Insulin secretion from H4IIE/ND and H4IIEins/ND cells: (A) dose response curve to 
increasing concentrations of glucose, 0–20 mmol/L; (B) response to 10 mmol/L theophylline;  
and (C) 10 mmol/L calcium. Cells were incubated in the basal medium for two consecutive 1 h 
periods (Basal 1 and 2) before exposure to the stimulus for 1 h, followed by a third basal period  
(Basal 3). Values are expressed as means ± SE (n = 6). 
2.2. Transmission Electron Microscopy of Insulin Storage Granules 
To determine if secretory granules were present in H4IIE/ND and H4IIEins/ND cells  
transmission electron microscopy (TEM) and immunoelectron microscopy (IEM) were performed. 
TEM revealed the presence of granules in the cytoplasm (270–330 nm in diameter) in H4IIEins/ND 
cells (Figure 2A), which were of a similar appearance and dimension to those in pancreatic  
β-cells [23]. Few cytoplasmic granules of this size were found in the H4IIE/ND cells (Figure 2B), 
although some smaller granules (150 nm diameter) were present, in accordance with the low amount 
of insulin that was stored by this cell line. The IEMs indicated that both H4IIE/ND and H4IIEins/ND 
cells stored insulin within granules in the cytoplasm of the cells (Figure 2B insert, C). Further, 
immunogold labelling revealed that the insulin-containing granules in H4IIEins/ND cells were of a 
similar size and density to those observed in the mouse β-cell line, MIN6 [21] (Figure 2D). 
 
Figure 2. Cont. 
  
Figure 1. Insulin secretion from H4IIE/ND and H4IIEins/ND cells: (A) dose response curve to
increasing concentrations of glucose, 0–20 mmol/L; (B) response to 10 mmol/L theophylline; and (C)
10 mmol/L calcium. Cells were incubated in the basal medium for two consecutive 1 h periods (Basal 1
and 2) before exposure to the stimulus for 1 h, followed by a third basal period (Basal 3). Values are
expressed as means ˘ SE (n = 6).
2.2. Transmission Electron Microscopy of Insulin Storage Granules
To determine if secretory granules were present in H4IIE/ND and H4IIEins/ND cells transmission
electron microscopy (TEM) and immunoelectron microscopy (IEM) were performed. TEM revealed
the presence of granules in the cytoplasm (270–330 nm in diameter) in H4IIEins/ND cells (Figure 2A),
which were of a similar appearance and dimension to those in pancreatic β-cells [23]. Few cytoplasmic
granules of this size were found in the H4IIE/ND cells (Figure 2B), although some smaller granules
(150 nm diameter) were present, in accordance with the low amount of insulin that was stored by
this cell line. The IEMs indicated that both H4IIE/ND and H4IIEins/ND cells stored insulin within
granules in the cytoplasm of the cells (Figure 2B insert, C). Further, immunogold labelling revealed
that the insulin-containing granules in H4IIEins/ND cells were of a similar size and density to those
observed in the mouse β-cell line, MIN6 [21] (Figure 2D).
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followed by an immediate reversion to hyperglycaemia (Figure 3A). On removal, the grafts were 
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Figure 2. Transmission electron micrographs of: (A) H4IIEins/ND cells showing secretory granules
(SG) surrounded by a pale halo; (B) H4IIE/ND cells showing immature secretory granules (marked
with black arrows) and one larger secretory granule with a pale halo (marked by white arrow). The
insert shows an immunoelectron micrograph (IEM) of a granule labelled with 10 nm gold particles;
(C) IEM of H4IIEins/ND cells; and (D) MIN6 cells showing secretory granules labelled with 10 nm
gold particles to show where insulin was stored in the cells (selected granules marked with arrows).
2.3. Reversal of Diabetes in Non-Obese Diabetic/Severe Combined Immunodeficiency (NOD/Scid) Mice
To determine if H4IIEins/ND cells could reverse diabetes in NOD/scid mice 1 ˆ 107 cells were
transplanted subcutaneously. Transplanted H4IIEins/ND cells combined into a mass at the site of
injection and grafts could be seen under the skin 1–2 weeks post-transplantation. All seen diabetic
mice that were transplanted with H4IIEins/ND cells reverted to normoglycaemia (blood glucose
4.5–5.0 mmol/L) within 14 days. Blood glucose levels of animals transplanted with H4IIEins/ND cells
remained normoglycemic until removal of the graft (day 24 post-transplantation), which was followed
by an immediate rev rsion to hyperglycaemia (Figure 3A). On r moval, the grafts were approximately
2–3 mm in diameter. These results indicated that reversal of hyperglcemia was attributable to the
transplanted H4IIEins/ND cells and not to the regeneration of pancreatic β-cells.
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Figure 3. Reversal of diabetes in NOD/scid mice after transplantation f H4IIEins/ND cells:
(A) blo d glucose levels of NOD/scid mice following transplant tion with H4IIEins/ND cells, together
with diabetic controls. Grafts of H4IIEins/ND cells were removed at 24 days; and (B) intraperitoneal
glucose tolerance test in mice following transplantation with H4IIEins/ND cells, together with normal
(non-diabetic) and diabetic controls. Values are expressed as mean ˘ SEM (n = 7).
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The fasting blood glucose levels of mice following transplantation with H4IIEins/ND cells were
not significantly lower than untreated normal control animals (Figure 3B). During the intraperitoneal
glucose tolerance tests (IPGTTs), the glucose dose response curves for mice transplanted with
H4IIEins/ND cells peaked at significantly lower blood glucose concentrations (8.0 ˘ 0.6 mmol/L),
as compared to normal untreated animals (20.6 ˘ 3.7 mmol/L), and by 60 min blood glucose
concentrations had returned to normal levels (4.5 ˘ 0.3 mmol/L glucose).
2.4. Immunohistochemistry of Islet Hormones in Transplanted H4IIEins/ND Cells
After removal at day 24, grafts of H4IIEins/ND cells were examined for double-staining of insulin
and NEUROD1 and triple-staining for the endocrine hormones insulin, glucagon, and somatostatin.
Extensive staining for human insulin and NEUROD1 was seen in H4IIEins/ND grafts removed
from animals (Figure 4A). The percentage of cells that stained positive for insulin, NEUROD1 and
insulin + NEUROD1 was 50 ˘ 1.0, 56.8 ˘ 2.0 and 44 ˘ 1.8 (n = 10 sections), respectively. The
remainder of the graft was composed of vascular and connective tissue. We examined pancreatic
hormone-producing cells in the H4IIEins/ND grafts. Tissue close to the graft was negative for both
insulin and NEUROD1 (Figure 4B). Figure 4C shows staining for insulin (52.8% ˘ 10%), glucagon
(0.3% ˘ 0.1%) and somatostatin (3.8% ˘ 1.1%), with a small number of cells being positive for all three
hormones (0.9% ˘ 0.4%) (n = 10 sections). Figure 4D shows a large amount of staining for insulin in
pancreatic islets from non-diabetic NOD/scid mice. However, pancreatic β-cells were rarely seen in
diabetic animals that were transplanted with H4IIEins/ND cells (Figure 4E).
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Figure 4. Expression of pancreatic hormones and NEUROD1 in grafts from NOD/scid mice following
transplantation of H4IIEins/ND cells and diabetes reversal. Photomicrographs of double-stained
anti-insulin and anti-NEUROD1 of (A) H4IIEins/ND cells; and (B) tissue near graft (bar = 80 µm);
(C–E): Photomicrographs of triple anti-insulin (INS), anti-glucagon (GLUC) and anti-somatostatin (SST)
staining of (C) H4IIEins/ND graft; (D) normal mouse pancreas; and (E) diabetic mouse pancreas (bar
= 80 µm). Original magnification 200ˆ.
2.5. Expression of β-Cell Related Genes in H4IIEins and H4IIEins/ND Cells
To determine if the pancreatic transdiffereniation seen in H4IIE/ND and H4IIEins/ND cells is
a result of induced expression of β-cell transcription factors, reverse transcription polymerase chain
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reaction (RT-PCR) and real time quantitative polymerase chain reaction (RT-qPCR) was performed. As
expected, H4IIEins and H4IIEins/ND cells expressed INS-FUR and H4IIE/ND, and H4IIEins/ND
cells expressed NeuroD1 (Figure 5A). Expression of NeuroD1 in both the H4IIE/ND and H4IIEins/ND
cells stimulated expression of both upstream (Pdx1) and downstream (NeuroD1, Pax4, Nkx2.2, Nkx6.1)
β-cell transcription factors. Neurog3 was not detected in any of the cell lines and Pax 6 was detected
in all cell lines, including the parent cell line, H4IIE. Rat insulin 1 and 2, somatostatin, glucagon, and
pancreatic polypeptide were expressed in the H4IIE/ND and the H4IIEins/ND cells. MafA and Kir 6.2
were expressed in all cell lines, with the exception of the H4IIE cells. MafB and the channel proteins
SUR2A, SUR2B, and Kir 6.1 were expressed in all cell lines, as were rat glucokinase and GLUT2. The
exocrine factor, p48, was not expressed in any of the cell lines (Figure 5B).
Examination of the expression levels of several key β-cell transcription factors by qRT-PCR
indicated that there was an 8.9 ˘ 0.5-fold increase in Pdx-1, a 6.5 ˘ 0.4-fold increase in NeuroD1,
a 9.6 ˘ 1.7 increase in rat Nkx2.2, a 4.5 ˘ 0.9-fold increase in rat insulin 1, and a 2.3 ˘ 0.4-fold increase
in rat insulin 2 expression in H4IIEins/ND cells (n = 6), as compared to H4IIE/ND cells. By comparison,
there were no differences in the expression levels of the other factors examined between the two cell
lines (Figure 5B).
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Figure 5. Pancreatic hormones and β cell transcription factors expressed in rat liver cell lines.
(A) reverse transcription polymerase chain reaction (RT-PCR)analysis of cell lines for INS-FUR,
NeuroD1 and β-actin (Actb): H4IIE (lane 1), I ins (lane 2), H4IIE/ND (lane 3), and H4IIEins/ND
(lane 4); (B) RT-PCR nalysis for: β cell transcripti f t rs (Pdx1, Neurog3, NeuroD1, Nkx2-2, Nkx6-1,
Pax6, MAFA, MAFB); the rat pancreatic endocrine hormones insulin 1 and 2 (Ins1, Ins2), glucagon (Gcg),
somatostatin (Sst), and pancreatic polypeptide (Ppy); GLUT2 (Slc2a2) and glucokinase (Gck); insulin
proconvertase PC1 (PC1) and PC2 (PC2); the exocrine marker p48; the potassium channel proteins SUR
2A, SUR2B, Kir 6.1 and Kir 6.2 and β-actin in H4IIE (lane 1), H4IIEins (lane 2), H4IIE/ND (lane 3),
H4IIEins/ND (lane 4), and rat pancreatic tissue (lane 5).
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3. Discussion
In the current study, the rat liver cell line, H4IIE, which, like primary hepatocytes, does not express
major β-cell transcription factors, was engineered to express INS-FUR together with rat NeuroD1
(H4IIEins/ND cells). These cells developed insulin storage granules and, following transplantation,
reversed diabetes in NOD/scid mice (Figure 3A). The H4IIEins/ND cells expressed β-cell transcription
factors and exhibited regulated insulin secretion. In the presence of NeuroD1 alone (H4IIE/ND cells),
β-cell transcription factors were expressed, but insulin storage was very low and glucose-responsive
insulin secretion was absent. These results support our previous findings [14–18] that, under certain
conditions, the dual expression of insulin and a β-cell transcription factor is superior to the expression
of insulin or the β-cell transcription factor alone [9–13,24–26].
In a pancreatic β-cell, regulated physiological secretion of insulin is facilitated by the storage of
insulin in secretory granules in the cytoplasm. Previous studies have shown that the development of
secretory granules in liver cells can be induced by the expression of various β-cell transcription factors.
Ferber et al. [9] delivered Pdx1 to mouse liver tissue, via recombinant adenovirus-mediated transfer,
and showed that expression of Pdx-1 in the livers of diabetic mice resulted in insulin expression
and secretion with restoration of normoglycaemia due to hepatic insulin production. However,
normoglycaemia was transient (only sustained for eight days) and exocrine transdifferentiation of the
liver resulted in the development of hepatitis. Kojima et al. [11] observed similar exocrine differentiation
after delivery of Pdx1 to mouse livers, which was likely attributable to the use in the study of a powerful
ubiquitously expressed elongation factor-1α promoter, resulting in constitutive high level expression
of Pdx-1. Kojima et al [11] also incorporated NeuroD1 together with βcellulin within an adenoviral
vector and transduced the livers of streptozotocin (STZ)-treated diabetic mice. It was found that the
expression of NeuroD1-βcellulin reversed diabetes and maintained normoglycaemia, with associated
up-regulation of both upstream and downstream β-cell transcription factors, including Pdx1, Pax6,
Pax4, Nkx2.2, and Nkx6.1, as seen in the current study. This up-regulation of Pdx1 may be a method (as
suggested by Kojima et al. [11]) by which NeuroD1, in a “feed-forward fashion, induces neogenesis
of all major hormone producing cells in the newly formed islets”. This same mechanism may have
occurred in the H4IIE/ND and H4IIEins/ND cell lines following transduction with NeuroD1. In the
Kojima study insulin storage levels were low [11], as observed in the H4IIE/ND cells. By comparison,
the insulin content of the H4IIEins/ND cells was not significantly different to the MIN6 β-cell line. The
H4IIEins cell line that expressed no β-cell transcription factors simply secreted insulin in a constitutive
fashion with no detectable storage.
The granules in the H4IIEins/ND cells were similar in size and appearance to those seen in
normal pancreatic β-cells, and to those observed in Melligen cells and NOD mice that have been
engineered to express insulin in their livers [15,17]. The granules in the H4IIEins/ND cells were typical
of mature β-cell granules which have an electron-dense core and a granule-limiting membrane with
the presence of a halo around the core [23]. The amount of immunogold staining in H4IIEins/ND cells
was comparable to that seen in MIN6 cells, which correlated with the similarly large amount of insulin
that was stored in the two cell lines. By comparison, the granules of H4IIE/ND cells were sparse and
looked immature in appearance. Only small numbers of granules were detected in H4IIE/ND cells,
which correlates with the comparably low storage of insulin. Extraction of the cells with acid/ethanol
indicated that both rat and human insulin was stored in the granules of H4IIE/ND and H4IIEins/ND
cells, with a significantly greater proportion of human insulin.
The expression of the β-cell transcription factor, NeuroD1, most likely stimulated the expression
of the network of transcriptional factors required for pancreatic neogenesis in H4IIE/ND and
H4IIEins/ND cells, including upstream expression of Pdx1 and the other major factors involved
in islet development, including Nkx2.2 and Nkx6.1. The net result was the expression of the rat
pancreatic hormones insulin, glucagon, somatostatin, and pancreatic polypeptide. MafA was expressed
in all transduced cell lines, including H4IIEins cells, and whilst the role of MafA in the development
of the pancreatic β-cells has not been fully delineated, it is thought to be a mediator of insulin gene
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transcription [27]. In contrast to our previous studies [16,17], the proconvertases, PC1 and PC2, were
also expressed in both H4IIE/ND and H4IIEins/ND cells. MafB was expressed in all cell lines, which
was not unexpected as it has been reportedly expressed in liver tissue [17,27]. The expression of the
potassium channel subunits (SUR1, SUR2, Kir 6.1) in all the cell lines and the expression of Kir 6.2 in
all the transduced cell lines is consistent with observations that these channels are expressed in liver
tissue [27–29]. Previous studies using other cell lines, which have been induced to secrete insulin in
a regulated fashion, have shown that responsiveness to glucose, and other pharmacological stimuli,
occurs through the activation of ATP-sensitive potassium and calcium channels [28–30], which may
be the case in the current study, but this would require confirmation. The exocrine marker, p48, was
not expressed in any of the transduced cells, thereby preventing exocrine transdifferentiation which
would have caused cell destruction, as reported in other studies [9,11].
The H4IIEins/ND cell line commenced increased secretion of insulin to glucose at 2.5 mmol/L,
which is less sensitive than pancreatic β-cells, which respond in the 4–5 mmol/L range, but identical
to HEPGins/g and Huh7ins cells [14,31] that were engineered to secrete insulin in the presence of the
endogenous expression of β-cell transcription factors. In the Huh7ins cells [14,15], the suboptimal
response to glucose was a result of higher expression levels of hexokinase, as compared to glucokinase.
When islet glucokinase was expressed in the Huh7ins cells, the resulting Melligen cell line responded
to glucose in the physiological range [15]. When transplanted into diabetic NOD/scid mice, the
H4IIEins/ND cells achieved normoglycaemia; however, normal glucose tolerance was not observed,
with IPGTTs showing peak responses at a much lower value than for normal animals, which was
similar to the result observed using Huh7ins cells [14]. This anomaly was corrected in the Melligen
cell line when the glucokinase: the hexokinase ratio was adjusted in favor of glucokinase (as is
observed in pancreatic β-cells) and normal glucose tolerance was established. The H4IIEins/ND cells
also responded well to a calcium and theophylline stimulus, whilst H4IIE/ND cells showed a small
response to calcium alone. In an attempt to understand why expression of INS-FUR and NeuroD1
resulted in significantly increased secretion of insulin to glucose (and the other secretogogues tested),
we performed RT-qPCR to compare expression levels of the β-cell transcription factors and other
genes. Compared to the H4IIE/ND cells, the H4IIEins/ND cells showed a significant up-regulation of
expression of several key β-cell transcription factors, Pdx1, NeuroD1, and Nkx2.2, and the rat insulin
genes 1 and 2, which likely produced a more mature β-cell phenotype, characterized by a greater
number of insulin secretory granules and regulated glucose-stimulated insulin release. However, the
reason why the dual expression of INS-FUR and NeuroD1 has resulted in extensive storage of the
INS-FUR and regulated secretion of human, rather than rat insulin, to glucose is yet to be elucidated.
The expression of NeuroD1 undoubtedly resulted in secretory granule biogenesis, and because INS-FUR
is overexpressed in the H4IIEins/ND cells the cells likely produced increased amounts of human, as
compared to rat insulin. Feedback mechanisms are probably activated when a liver cell produces large
amounts of insulin in the presence of β-cell transcription factors; however, these are not currently
identified. Indeed, the pathways of β-cell transcription factors and their interactions are continually
being elucidated and updated [5] and ongoing studies in our laboratory, and others, will likely lead to
greater understanding of the pathways in the future.
The H4IIEins/ND cell line is not a clinically relevant system as, most importantly, it is derived
from a tumorigenic rat liver cell line. Additionally, whilst a retroviral vector [32] was utilized in this
model system as a tool to investigate the dual expression of NeuroD1 and human insulin in a liver
cell, there are concerns with the clinical application of these vectors in that they may induce oncogene
expression when the residual viral genome is integrated close to the location of an oncogene region in
the host genome [33]. Secondly, they only transduce dividing cells [34]. More appropriate vectors for
clinical application would be lentiviral vectors that can transduce quiescent cells without a significant
immune response [17,34] or adeno-associated vectors (AAV), which allow site-specific integration of
transgenes into the host chromosome and new developments describe AAV cassettes that specifically
transduce human cells [35].
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4. Materials and Methods
4.1. Vectors
The INS-FUR gene [19] (gift from Genetech, San Franscico, CA, USA) and/or the rat NeuroD1
gene were cloned into the retroviral vector pLXSN [21] (gift from G. Marshall, Children’s Cancer
Institute, Randwick, NSW, Australia) between the HpaI and XhoI sites. The bicistronic segment
containing the genes was constructed in the pGEM2-derived vector pSXLC in which the internal
ribosomal entry site had been inserted into the modified multi-cloning site of the vector [32] (gift
from T. Friedmann, Centre for Molecular Genetics, University of California, San Diego, CA, USA). All
molecular manipulations were approved by the University of Technology Sydney (UTS), Biosafety
Committee, (Protocol 2011-23-R-GC). A schematic representation of the vectors can be found in
Figure S1. Retroviral vector constructs containing INS-FUR and/or NeuroD1 or empty vector were
introduced into the amphotrophic packaging cell line, PA317. The medium from the PA317 cell line was
used to transduce the H4IIE cells. Stable clones were selected in G418 (1.4 µg/mL, Life Technologies,
Mulgrave, VIC, Australia) and expanded for further analysis: H4IIE-EV (empty vector), H4IIEins cells
(INS-FUR gene alone), H4IIE/ND (NeuroD1 gene alone), and H4IIEins/ND (INS-FUR and NeuroD1
genes). At least 10 clones were isolated from each group and the cell line with the highest level of
insulin storage was selected for further experimentation.
4.2. Cell Culture
The amphotrophic cell line, PA317 was obtained from G. Marshall (Children’s Cancer Institute,
Randwick, NSW, Australia) and the H4IIE parent cell line was obtained from the American Type
Culture Collection (Manassas, VA, USA). Cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Trace Biosciences, Castle Hill, NSW, Australia), containing 4.5 g/L glucose,
supplemented with 44 mmol/L sodium bicarbonate and 10% fetal calf serum (FCS, Trace Biosciences)
and 5% CO2/37 ˝C in a humidified incubator. MIN6 cells [17] were grown in the presence of 15% v/v
FCS. H4IIEins cells, H4IIE/ND and H4IIEins/ND were grown in the presence of 10% v/v FCS and
G418 (1.4 µg/mL) to maintain selective pressure.
4.3. Insulin Secretion and Storage
To determine if the cell lines stored insulin, 5 ˆ 106 cells were re-suspended in 500 NOD/scid of
0.18 N HCl in 70% ethanol for 48 h at 4 ˝C. For the measurement of insulin content, samples were
diluted (1:10 or 1:100) and insulin levels were measured using an ELISA kit (EZHI-14K, Merck Millipore,
MA, USA), which had no cross-reactivity with human proinsulin or rat insulin. For the measurement
of rat insulin the EZRMI-12K kit (Merck Millipore) was used, which had no cross-reactivity with
human insulin. To determine acute secretion of insulin to stimuli, tissue culture wells were washed
with basal medium (phosphate buffered saline [PBS] containing 1 mmol/L CaCl2 and supplemented
with 20 mmol/L HEPES and 2 mg/mL bovine serum albumin [BSA], 2.8 mmol/L glucose, (unless
otherwise stated), pH 7.4. Monolayers were incubated in the basal medium for two consecutive 1 h
periods to obtain a basal insulin reading. Monolayers were then exposed to stimuli for a further
period of 1 h. The effect of increasing concentrations of glucose (from 0 to 20 mmol/L), theophylline
(10 mmol/L) and calcium (10 mmol/L) on acute insulin secretion was assessed by ELISA.
4.4. Transplantation of Engineered Cells
Male NOD/scid mice were sourced from the Australian Research Council (ARC) Facility (Perth,
WA, Australia). All animal studies were performed according to the guidelines of the National Health
and Medical Research Council of Australia principles of animal care and regulations of the ARC,
following approval by the Animal Care and Ethics Committee at UTS (Protocol 2008-37). Injection of
STZ, (170 mg/kg) induced diabetes in the mice. After treatment, animals were monitored for blood
glucose and body weight change. Diabetes was defined as three consecutive blood glucose readings
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>15mmol/L. Rat pancreatic tissue was sourced from male Wistar rats (Gore Hill Research Laboratories,
Sydney, NSW, Australia) with ethics approval as above.
H4IIEins/ND cells (1 ˆ 107) (n = 6) were aspirated into a syringe with a 21 g needle, and
injected subcutaneously above the right scapula of the mice. Weight and blood glucose levels were
monitored every 1–3 days. No insulin was given to the mice during the experiment. Intraperitoneal
glucose tolerance tests (IPGTT) (2 g glucose/kg after a 6 h fast) were carried out on the animals
transplanted with H4IIEins/ND cells prior to removal of the grafts together with diabetic and normal
control animals.
4.5. Microscopic Analysis
For immunofluorescence, frozen sections (6–8 µm) of pancreas and transplanted H4IIEins/ND
cells were cut. For the triple staining of insulin, somatostatin, and glucagon, the primary antibodies
were mouse anti-human insulin (1:100 BioGenex, Fremont, CA, USA), goat anti-somatostatin, and goat
anti-glucagon (1:200, Santa Cruz, CA, USA). The secondary antibodies used were anti-mouse IgG for
insulin, and anti-goat IgG for somatostatin and glucagon (1:200, Vector, Laboratories, Burlingame, CA,
USA). The fluoresceins used were avidin D, rhodamine avidin D, and AMCA avidin D (1:200, Vector
Burlingame, CA, USA). The fluorescein M.O.M kit (FMK–220, Vector Laboratories, Burlingame, CA,
USA) was used for staining, following the manufacturer’s instructions. The avidin/biotin blocking kit
(sp-200, Vector, CA, USA) was used, as per the manufacturer’s instructions, between applications of the
different antibodies during the triple-staining procedure. For double-staining of insulin and NeuroD1,
the sections of transplanted cells were incubated (1 h) with mouse anti-human insulin (1:100 BioGenex,
Fremont, CA, USA) and goat anti-NeuroD1 (Santa Cruz, CA, USA), which were diluted 1:100 in 10%
donkey serum at room temperature (RT). The secondary antibodies were subsequently incubated
at RT (1 h) in the case of insulin, with FITC-conjugated donkey anti-mouse IgG, or rhodamine red
conjugated donkey anti-goat IgG for NeuroD1 (Jackson ImmunoReseach, Westgrove, PA, USA), which
was diluted 1:100 in 10% donkey serum and incubated for 1h at RT. Vectashield mounting medium
(Vector Labratories, Burlingame, CA, USA) was used to mount sections which were examined under
an Olympus BX60 fluorescent microscope. Analysis of the data was performed using the Olympus
Image Pro 6.2 software (Media Cybernetics, Inc., Rockville, MD, USA).
For electron microscopy, cells were fixed and processed as previously described [17]. For insulin
IEM, a post-embedding immunogold procedure was used. Cells were embedded in LR white and
labelling procedures were performed as previously described [17].
4.6. RT-PCR and RT-qPCR Analysis of Gene Expression
For RT-PCR analyses, H4IIE, H4IIEins, H4IIE/ND, and H4IIEins/ND were snap-frozen in liquid
nitrogen. Rat pancreas was used as the positive control. Total RNA was extracted with Trizol
(Invitrogen/ ThermoFisher Scientific, Waltman, MA, USA) and samples were treated with DNase I
(Invitrogen). Levels of expression of INS-FUR, other pancreatic hormones (rat insulin 1 and 2, glucagon,
somatostatin, pancreatic polypeptide), liver glucokinase, GLUT2, the proconvertases, PC1 and PC2,
several β-cell transcription factors (Pdx-1, NeuroD1, Neurog3, Nkx2.2, Nkx6.1, Pax4, Pax6), MafA, MafB,
and the channel proteins, SUR2A, SUR2B, Kir6.1, and Kir 6.2, were determined.
cDNA was used as the template for real-time RT-qPCR using the SYBR GreenER qPCR Supermix
(Invitrogen). The Eppendorf Realplex2 was the detection system. Real-time RT-qPCR reactions
contained either primers specific to the reference gene, β-actin or the gene of interest (Table S1).
Data was analysed using the 2´∆∆t method: ∆∆CT = (Ct, target ´ Ct, reference)control tissue ´ (Ct, target ´
Ct, reference)sample tissue. The fold change in the expression of the target gene was normalised to β-actin
and was relative to the expression in the control tissue. Means and standard error of the mean (SEMs) in
fold changes in expression for each gene of interest were calculated. Oligonucleotide primer sequences
can be found in Table S1.
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4.7. Statistical Analysis
Data are represented as mean values ˘ SEMs. Comparisons between two groups were analysed
using Student’s t-test. Comparisons between more than two groups were calculated using ANOVA
(SPSS 17.0.0, SPSS Inc. 2008, Softonic, Barcelona, Spain). Repeated-measures analyses were used where
it was appropriate. p Values <0.05 were considered to be statistically significant.
5. Conclusions
In conclusion, this study is the first to show increased insulin storage and secretion of insulin to
glucose following the dual expression of NeuroD1 and insulin in liver cells and gives promise that this
gene combination delivered by a clinically applicable vector system is a viable strategy to ameliorate
diabetes in insulin-dependent individuals.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/
4/534/s1.
Acknowledgments: This research was supported by a grant from the University of Technology Sydney (UTS)
and a Postdoctoral Fellowship (CT) from the Centre for Health Technologies (UTS). Dario Gerace (UTS) drew the
vector schematic diagram and Richard Limburg provided IT support.
Author Contributions: Ann. M. Simpson, Binhai Ren, Chang Tao, Margaret Anne Swan, Nichole Joachim,
Najah. T. Nassif and Bronwyn. A. O’Brien conceived and designed the experiments; Binhai Ren, Chang Tao
and Nichole Joachim performed the experiments; Ann. M. Simpson, Binhai Ren, Chang Tao, Margaret Anne
Swan, Nichole Joachim, Najah. T. Nassif and Bronwyn. A. O’Brien analyzed the data; Binhai Ren, Chang Tao,
Margaret Anne Swan, Nichole Joachim, Najah. T. Nassif, Bronwyn. A. O’Brien and Rosetta Martiniello-Wilks
reviewed/edited the manuscript and contributed to the discussion; Ann. M. Simpson wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
T1D Type 1 diabetes
T2D Type 2 diabetes
IDF International Diabetes Federation
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